Literature DB >> 18820579

Preparing for the next influenza pandemic.

Jonathan A McCullers1.   

Abstract

There are 3 requirements for an influenza virus to cause a pandemic. It must be antigenically novel, cause severe disease, and transmit easily from human to human. Highly pathogenic avian influenza viruses of the H5N1 subtype currently circulating in bird populations in Asia, Africa, and Europe have met 2 of these criteria, and there is significant concern that these viruses will be the cause of the next pandemic. International efforts to prepare for a possible pandemic are underway. Priorities for pandemic planning include surveillance of influenza viruses in wild bird populations and at the avian-human interface, research into factors affecting the pathogenicity of these strains, stockpiling effective antivirals for use as a stopgap until an appropriate vaccine can be developed and distributed, and gaining an improved understanding of the utility of nonpharmaceutical interventions to slow or prevent the spread of these viruses within humans. Although considerable progress has been made in recent years towards readying the world for such an event, there is more work to be done. Physicians and hospitals can begin by educating themselves on the problem and developing a pandemic plan for their own practice or organization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820579      PMCID: PMC2692546          DOI: 10.1097/INF.0b013e3181684d41

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  31 in total

1.  Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply.

Authors:  Jeroen K Medema; York F Zoellner; James Ryan; Abraham M Palache
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

Review 2.  Influenza: emergence and control.

Authors:  Aleksandr S Lipatov; Elena A Govorkova; Richard J Webby; Hiroichi Ozaki; Malik Peiris; Yi Guan; Leo Poon; Robert G Webster
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 3.  Evolution and ecology of influenza A viruses.

Authors:  R G Webster; W J Bean; O T Gorman; T M Chambers; Y Kawaoka
Journal:  Microbiol Rev       Date:  1992-03

4.  Influenza pandemics in perspective.

Authors:  E D Kilbourne
Journal:  JAMA       Date:  1977-03-21       Impact factor: 56.272

5.  Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003.

Authors:  K M Butt; Gavin J D Smith; Honglin Chen; L J Zhang; Y H Connie Leung; K M Xu; Wilina Lim; Robert G Webster; K Y Yuen; J S Malik Peiris; Yi Guan
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

6.  Human infection with influenza H9N2.

Authors:  M Peiris; K Y Yuen; C W Leung; K H Chan; P L Ip; R W Lai; W K Orr; K F Shortridge
Journal:  Lancet       Date:  1999-09-11       Impact factor: 79.321

7.  A pandemic warning?

Authors:  J C de Jong; E C Claas; A D Osterhaus; R G Webster; W L Lim
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

8.  H5N1 influenza: a protean pandemic threat.

Authors:  Y Guan; L L M Poon; C Y Cheung; T M Ellis; W Lim; A S Lipatov; K H Chan; K M Sturm-Ramirez; C L Cheung; Y H C Leung; K Y Yuen; R G Webster; J S M Peiris
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

9.  Containing pandemic influenza with antiviral agents.

Authors:  Ira M Longini; M Elizabeth Halloran; Azhar Nizam; Yang Yang
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

Review 10.  Are we ready for pandemic influenza?

Authors:  Richard J Webby; Robert G Webster
Journal:  Science       Date:  2003-11-28       Impact factor: 47.728

View more
  8 in total

Review 1.  The influenza pandemic of 2009: lessons and implications.

Authors:  Paul Shapshak; Francesco Chiappelli; Charurut Somboonwit; John Sinnott
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

2.  Molecular signatures of virulence in the PB1-F2 proteins of H5N1 influenza viruses.

Authors:  Amber M Smith; Jonathan A McCullers
Journal:  Virus Res       Date:  2013-03-14       Impact factor: 3.303

3.  PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology.

Authors:  Julie L McAuley; Jerry E Chipuk; Kelli L Boyd; Nick Van De Velde; Douglas R Green; Jonathan A McCullers
Journal:  PLoS Pathog       Date:  2010-07-22       Impact factor: 6.823

4.  Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza.

Authors:  Asa Karlström; Kelli L Boyd; B Keith English; Jonathan A McCullers
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

5.  Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.

Authors:  Joshua M Klonoski; Heather R Hurtig; Brian A Juber; Margaret J Schuneman; Thomas E Bickett; Joshua M Svendsen; Brandon Burum; Thomas A Penfound; Grigoriy Sereda; James B Dale; Michael S Chaussee; Victor C Huber
Journal:  Vaccine       Date:  2014-07-29       Impact factor: 3.641

6.  Influenza A(H5N1) vaccines: are we better prepared for the next pandemic?

Authors:  Wendy A Keitel; Pedro A Piedra
Journal:  J Infect Dis       Date:  2013-10-24       Impact factor: 5.226

7.  Outbreak Response and Incident Management: SHEA Guidance and Resources for Healthcare Epidemiologists in United States Acute-Care Hospitals.

Authors:  David B Banach; B Lynn Johnston; Duha Al-Zubeidi; Allison H Bartlett; Susan Casey Bleasdale; Valerie M Deloney; Kyle B Enfield; Judith A Guzman-Cottrill; Christopher Lowe; Luis Ostrosky-Zeichner; Kyle J Popovich; Payal K Patel; Karen Ravin; Theresa Rowe; Erica S Shenoy; Roger Stienecker; Pritish K Tosh; Kavita K Trivedi
Journal:  Infect Control Hosp Epidemiol       Date:  2017-11-30       Impact factor: 3.254

Review 8.  Therapeutics against influenza.

Authors:  Elena A Govorkova; Jonathan A McCullers
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.